Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Diabetes ; 70(7): 1443-1457, 2021 07.
Article in English | MEDLINE | ID: mdl-33883213

ABSTRACT

The counterregulatory response to hypoglycemia is an essential survival function. It is controlled by an integrated network of glucose-responsive neurons, which trigger endogenous glucose production to restore normoglycemia. The complexity of this glucoregulatory network is, however, only partly characterized. In a genetic screen of a panel of recombinant inbred mice we previously identified Fgf15, expressed in neurons of the dorsomedial hypothalamus (DMH), as a negative regulator of glucagon secretion. Here, we report on the generation of Fgf15CretdTomato mice and their use to further characterize these neurons. We show that they were glutamatergic and comprised glucose-inhibited and glucose-excited neurons. When activated by chemogenetics, Fgf15 neurons prevented the increase in vagal nerve firing and the secretion of glucagon normally triggered by insulin-induced hypoglycemia. On the other hand, they increased the activity of the sympathetic nerve in the basal state and prevented its silencing by glucose overload. Higher sympathetic tone increased hepatic Creb1 phosphorylation, Pck1 mRNA expression, and hepatic glucose production leading to glucose intolerance. Thus, Fgf15 neurons of the DMH participate in the counterregulatory response to hypoglycemia by a direct adrenergic stimulation of hepatic glucose production while suppressing vagally induced glucagon secretion. This study provides new insights into the complex neuronal network that prevents the development of hypoglycemia.


Subject(s)
Fibroblast Growth Factors/physiology , Glucagon/metabolism , Gluconeogenesis/physiology , Hypothalamus/metabolism , Liver/metabolism , Neurons/physiology , Animals , Cyclic AMP Response Element-Binding Protein/physiology , Female , Hypoglycemia/prevention & control , Male , Mice , Mice, Inbred C57BL , Sympathetic Nervous System/physiology
2.
Nat Commun ; 9(1): 546, 2018 02 07.
Article in English | MEDLINE | ID: mdl-29416045

ABSTRACT

Glucagon secretion by pancreatic α-cells is triggered by hypoglycemia and suppressed by high glucose levels; impaired suppression of glucagon secretion is a hallmark of both type 1 and type 2 diabetes. Here, we show that α-cell glucokinase (Gck) plays a role in the control of glucagon secretion. Using mice with α-cell-specific inactivation of Gck (αGckKO mice), we find that glucokinase is required for the glucose-dependent increase in intracellular ATP/ADP ratio and the closure of KATP channels in α-cells and the suppression of glucagon secretion at euglycemic and hyperglycemic levels. αGckKO mice display hyperglucagonemia in the fed state, which is associated with increased hepatic gluconeogenic gene expression and hepatic glucose output capacity. In adult mice, fed hyperglucagonemia is further increased and glucose intolerance develops. Thus, glucokinase governs an α-cell metabolic pathway that suppresses secretion at or above normoglycemic levels; abnormal suppression of glucagon secretion deregulates hepatic glucose metabolism and, over time, induces a pre-diabetic phenotype.


Subject(s)
Glucagon-Secreting Cells/metabolism , Glucagon/metabolism , Glucokinase/genetics , Glucose Intolerance/metabolism , Glucose/metabolism , Hypoglycemia/metabolism , Adenosine Diphosphate/metabolism , Adenosine Triphosphate/metabolism , Animals , Biological Transport , Female , Gene Expression , Glucagon-Secreting Cells/pathology , Glucokinase/deficiency , Glucose Intolerance/genetics , Glucose Intolerance/pathology , Hypoglycemia/genetics , Hypoglycemia/pathology , Insulin/metabolism , KATP Channels/genetics , KATP Channels/metabolism , Liver/metabolism , Male , Mice , Mice, Knockout
3.
Proc Natl Acad Sci U S A ; 110(24): 10004-9, 2013 Jun 11.
Article in English | MEDLINE | ID: mdl-23720317

ABSTRACT

NHA2 is a sodium/hydrogen exchanger with unknown physiological function. Here we show that NHA2 is present in rodent and human ß-cells, as well as ß-cell lines. In vivo, two different strains of NHA2-deficient mice displayed a pathological glucose tolerance with impaired insulin secretion but normal peripheral insulin sensitivity. In vitro, islets of NHA2-deficient and heterozygous mice, NHA2-depleted Min6 cells, or islets treated with an NHA2 inhibitor exhibited reduced sulfonylurea- and secretagogue-induced insulin secretion. The secretory deficit could be rescued by overexpression of a wild-type, but not a functionally dead, NHA2 transporter. NHA2 deficiency did not affect insulin synthesis or maturation and had no impact on basal or glucose-induced intracellular Ca(2+) homeostasis in islets. Subcellular fractionation and imaging studies demonstrated that NHA2 resides in transferrin-positive endosomes and synaptic-like microvesicles but not in insulin-containing large dense core vesicles in ß-cells. Loss of NHA2 inhibited clathrin-dependent, but not clathrin-independent, endocytosis in Min6 and primary ß-cells, suggesting defective endo-exocytosis coupling as the underlying mechanism for the secretory deficit. Collectively, our in vitro and in vivo studies reveal the sodium/proton exchanger NHA2 as a critical player for insulin secretion in the ß-cell. In addition, our study sheds light on the biological function of a member of this recently cloned family of transporters.


Subject(s)
Insulin-Secreting Cells/metabolism , Insulin/metabolism , Sodium-Hydrogen Exchangers/metabolism , Animals , Cell Line, Tumor , Endocytosis/drug effects , Endosomes/metabolism , Exocytosis/drug effects , Female , Glucose/pharmacology , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Humans , Insulin Secretion , Insulin-Secreting Cells/cytology , Insulin-Secreting Cells/drug effects , Male , Mice , Mice, Knockout , Microscopy, Confocal , RNA Interference , Sodium-Hydrogen Exchangers/genetics , Sulfonylurea Compounds/pharmacology
4.
Diabetes ; 57(3): 584-93, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18025410

ABSTRACT

OBJECTIVE: Glucagon-like peptide-1 (GLP-1) is a growth and differentiation factor for mature beta-cells and their precursors. However, the overall effect of GLP-1 on increasing beta-cell mass in both in vivo and in vitro conditions is relatively small, and augmenting this effect would be beneficial for the treatment or prevention of type 1 and type 2 diabetes. Here, we searched for cellular mechanisms that may limit the proliferative effect of GLP-1 and tested whether blocking them could increase beta-cell proliferation. RESEARCH DESIGN AND METHODS: We examined GLP-1-regulated genes in beta TC-Tet cells by cDNA microarrays. To assess the effect of some of these gene on cell proliferation, we reduced their expression using small heterogenous RNA in beta-cell lines and primary mouse islets and measured [(3)H]thymidine or 5'-bromo-2'-deoxyuridine incorporation. RESULTS: We identified four negative regulators of intracellular signaling that were rapidly and strongly activated by GLP-1: the regulator of G-protein-signaling RGS2; the cAMP response element-binding protein (CREB) antagonists cAMP response element modulator (CREM)-alpha and ICERI; and the dual specificity phosphatase DUSP14, a negative regulator of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase 1/2 (ERK1/2) pathway. We show that knockdown of CREMalpha or DUSP14 or expression of a dominant-negative form of DUSP14 increased beta-cell line proliferation and enhanced the GLP-1-induced proliferation of primary beta-cells. CONCLUSIONS: Together, our data show that 1) the cAMP/protein kinase A/CREB and MAPK/ERK1/2 pathways can additively control beta-cell proliferation, 2) beta-cells have evolved several mechanisms limiting GLP-1-induced cellular proliferation, and 3) blocking these mechanisms increases the positive effect of GLP-1 on beta-cell mass.


Subject(s)
Cyclic AMP Response Element Modulator/metabolism , Dual-Specificity Phosphatases/metabolism , Gene Silencing , Glucagon-Like Peptide 1/pharmacology , Insulin-Secreting Cells/cytology , Insulin-Secreting Cells/drug effects , Animals , Cell Line , Cell Proliferation/drug effects , Cells, Cultured , Cyclic AMP Response Element Modulator/genetics , Dose-Response Relationship, Drug , Dual-Specificity Phosphatases/genetics , Exenatide , Gene Expression Profiling , Glucose/metabolism , Glucose/pharmacology , Humans , Male , Mice , Oligonucleotide Array Sequence Analysis , Peptides/pharmacology , RGS Proteins/genetics , RGS Proteins/metabolism , Venoms/pharmacology
5.
EMBO J ; 23(3): 531-40, 2004 Feb 11.
Article in English | MEDLINE | ID: mdl-14749729

ABSTRACT

Phosphoinositides, synthesized from myo-inositol, play a critical role in the development of growth cones and in synaptic activity. As neurons cannot synthesize inositol, they take it up from the extracellular milieu. Here, we demonstrate that, in brain and PC12 cells, the recently identified H(+)/myo-inositol symporter HMIT is present in intracellular vesicles that are distinct from synaptic and dense-core vesicles. We further show that HMIT can be triggered to appear on the cell surface following cell depolarization, activation of protein kinase C or increased intracellular calcium concentrations. HMIT cell surface expression takes place preferentially in regions of nerve growth and at varicosities and leads to increased myo-inositol uptake. The symporter is then endocytosed in a dynamin-dependent manner and becomes available for a subsequent cycle of stimulated exocytosis. HMIT is thus expressed in a vesicular compartment involved in activity-dependent regulation of myo-inositol uptake in neurons. This may be essential for sustained signaling and vesicular traffic activities in growth cones and at synapses.


Subject(s)
Exocytosis/physiology , Growth Cones/metabolism , Membrane Proteins/metabolism , Monosaccharide Transport Proteins/metabolism , Synaptic Membranes/metabolism , Synaptic Vesicles/metabolism , Animals , Biological Transport/physiology , Brain/metabolism , Endocytosis/physiology , Glucose Transport Proteins, Facilitative , Inositol Phosphates/metabolism , PC12 Cells , Rats , Rats, Sprague-Dawley , Signal Transduction/physiology
6.
Diabetes ; 51(6): 1805-14, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12031968

ABSTRACT

Type 1 diabetes is characterized by the infiltration of activated leukocytes within the pancreatic islets, leading to beta-cell dysfunction and destruction. The exact role played by interferon-gamma, tumor necrosis factor (TNF)-alpha, and interleukin-1beta in this pathogenic process is still only partially understood. To study cytokine action at the cellular level, we are working with the highly differentiated insulin-secreting cell line, betaTc-Tet. We previously reported that it was susceptible to apoptosis induced by TNF-alpha, in combination with interleukin-1beta and interferon-gamma. Here, we report that cytokine-induced apoptosis was correlated with the activation of caspase-8. We show that in betaTc-Tet cells, overexpression of cFLIP, the cellular FLICE (FADD-like IL-1beta-converting enzyme)-inhibitory protein, completely abolished cytokine-dependent activation of caspase-8 and protected the cells against apoptosis. Furthermore, cFLIP overexpression increased the basal and interleukin-1beta-mediated transcriptional activity of nuclear factor (NF)-kappaB, whereas it did not change cytokine-induced inducible nitric oxide synthase gene transcription and nitric oxide secretion. The presence of cFLIP prevented the weak TNF-alpha-induced reduction in cellular insulin content and secretion; however, it did not prevent the decrease in glucose-stimulated insulin secretion induced by the combined cytokines, in agreement with our previous data demonstrating that interferon-gamma alone could induce these beta-cell dysfunctions. Together, our data demonstrate that overexpression of cFLIP protects mouse beta-cells against TNF-alpha-induced caspase-8 activation and apoptosis and is correlated with enhanced NF-kappaB transcriptional activity, suggesting that cFLIP may have an impact on the outcome of death receptor-triggered responses by directing the intracellular signals from beta-cell death to beta-cell survival.


Subject(s)
Apoptosis , Carrier Proteins/physiology , Caspases/metabolism , Insulin/metabolism , Intracellular Signaling Peptides and Proteins , Islets of Langerhans/metabolism , Tumor Necrosis Factor-alpha/pharmacology , Animals , CASP8 and FADD-Like Apoptosis Regulating Protein , Carrier Proteins/genetics , Caspase 8 , Caspase 9 , Cell Line , Enzyme Activation/drug effects , Gene Expression , Glucose/pharmacology , Humans , Insulin Secretion , Interferon-gamma/pharmacology , Interleukin-1/pharmacology , Islets of Langerhans/cytology , Mice , Mice, Transgenic , NF-kappa B/metabolism , Nitric Oxide/metabolism , Nitric Oxide Synthase/genetics , Nitric Oxide Synthase Type II , Recombinant Proteins , Transcription, Genetic , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...